Source/Disclosures
Source:

Press Release

Disclosures: Phillips is an employee of Novo Nordisk. Poppas reports no relevant financial disclosures.
September 12, 2020
1 min read
Save

Joint initiative launched to improve CV care of patients with type 2 diabetes

Source/Disclosures
Source:

Press Release

Disclosures: Phillips is an employee of Novo Nordisk. Poppas reports no relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The American College of Cardiology and Novo Nordisk announced the launch of a joint initiative, Transforming Cardiovascular Risk in Diabetes, to promote CV risk reduction among patients with type 2 diabetes.

The 2-year program (Transform CVRiD) will use real-world data from the ACC/Veradigm PINNACLE Registry and the Diabetes Collaborative Registry to identify care patterns that lead to optimal treatment, with the goal to develop tools and education to help physicians better treat patients with diabetes, according to a press release.

doctors collaborating
Source: Adobe Stock.
Athena Poppas

“Patients with diabetes face a very high risk of developing cardiovascular disease and require individualized care involving multiple specialties and therapies to ensure they are receiving the best possible care,” Athena Poppas, MD, FACC, president of the ACC, director of the Lifespan Cardiovascular Institute in Providence, Rhode Island and chief of cardiology and professor of medicine at the Warren Alpert School of Medicine at Brown University, said in the release. “This initiative will be critical to achieving a progressive path forward in the management of cardiovascular risk in type 2 diabetes.”

According to the release, select regional practices and hospitals will be identified to receive interventions that include education, quality improvement strategies and tools such as decision aids and checklists which would be administered via ACC Quality Ambassadors.

“Every physician treating someone with type 2 diabetes wants to have the confidence that they’re using the right medicine and applying the right guidelines at the right time. We have a great opportunity, based on our collective experience in diabetes and cardiovascular disease, to help health care professionals make evidence-based decisions to help their patients,” Anne Phillips, MD, senior vice president of clinical development, medical and regulatory affairs for Novo Nordisk, said in the release. “We’re looking forward to learning through this research, alongside our ACC partners, and implementing a program that can help improve the quality of care for people with type 2 diabetes and cardiovascular disease.”